ML385 Attenuates Malignant Progression of Silica-induced Lung Adenocarcinoma Cells through the ROS/NRF2-autophagy Axis Pathway
- 31 October 2025
- journal article
- video audio-media
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e69382
Abstract
Silica exposure is associated with an increased risk of lung adenocarcinoma, but its molecular mechanism remains unclear. This study aims to establish a repeatable experimental protocol to explore how the nuclear factor erythroid 2-related factor 2 (NRF2) inhibitor ML385 inhibits silica-induced malignant progression of lung adenocarcinoma by regulating the ROS/NRF2-autophagy axis pathway. Firstly, a silicosis model was established by intranasal perfusion of silica suspension in C57BL/6 mice. The degree of pulmonary fibrosis was evaluated by Masson staining, the infiltration of immune cells was analyzed by immunofluorescence, and the expressions of NRF2, cyclin-dependent kinase 1 (CDK1), and voltage-dependent anion channel 1 (VDAC1) in lung tissue were detected by immunohistochemistry. Subsequently, in in vitro experiments, the RAW264.7 macrophage cell line was treated with silica. Autophagic flux and oxidative stress levels were evaluated by LC3-lysosome co-localization and ROS probes, and intervention was carried out with the NRF2 inhibitor ML385. Finally, the effects of ML38 on migration, invasion, and apoptosis of lung adenocarcinoma cells were analyzed by scratch assay, cells passing through pores of a specific size assay, and flow cytometry. The results showed that silica could induce pulmonary fibrosis, immune cell infiltration, and upregulation of NRF2, CDK1, and VDAC1 in mice (p < 0.001), and inhibit the autophagic flux of macrophages and reduce ROS levels. ML385 can reverse these effects (p < 0.05). This protocol provides a complete experimental process from in vivo model construction to in vitro mechanism research, offering an operational technical path for studying the molecular mechanism of silica-related lung adenocarcinoma and therapeutic strategies targeting NRF2.Keywords
This publication has 34 references indexed in Scilit:
- SiO2 particles induce pulmonary fibrosis by modulating NLRP3 through the ROS/Keap1/Nrf2 signaling pathway in ratsFood and Chemical Toxicology, 2025
- Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancerCancer Cell, 2024
- Proteomic characteristics of lung adenocarcinoma tumors that are small but highly invasiveMedicine Advances, 2023
- Nebulized inhalation of LPAE-HDAC10 inhibits acetylation-mediated ROS/NF-κB pathway for silicosis treatmentJournal of Controlled Release, 2023
- The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2Cell Reports, 2023
- NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancerCell Metabolism, 2023
- The effect of silica exposure on the risk of lung cancer: A meta‐analysisJournal of Biochemical and Molecular Toxicology, 2023
- Melatonin Alleviates the Oxygen–Glucose Deprivation/Reperfusion-Induced Pyroptosis of HEI-OC1 Cells and Cochlear Hair Cells via MT-1,2/Nrf2 (NFE2L2)/ROS/NLRP3 PathwayMolecular Neurobiology, 2022
- Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistanceCancer Letters, 2019
- NRF2 and the Hallmarks of CancerCancer Cell, 2018